Get started
Work

Supplementary Table 2. from A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma

Year: 2023
Type: supplementary-materials
Abstract: Human anti-human antibody (HAHA) level and peak hu14.18K322A serum level by course and prior antibody therapy.
DOI: 10.1158/1078-0432.22468163.v1
Authors: Sara M. Federico, M. Beth McCarville, Barry L. Shulkin, Paul M. Sondel, Jacquelyn A. Hank, Paul Hutson, Michael Meagher, Aaron Shafer, Catherine Y. Ng, Wing Leung, William E. Janssen, Jianrong Wu, Shenghua Mao, Rachel C. Brennan, Victor M. Santana, Alberto S. Pappo, Wayne L. Furman
Language: English
Subfield: Neurology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4361931067
Cites:
Cited by:
Related to: 10